No abstract available
MeSH terms
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / genetics
-
Colorectal Neoplasms / mortality
-
Colorectal Neoplasms / pathology
-
Drug Combinations
-
Drug Resistance, Neoplasm
-
Gene Expression Regulation, Neoplastic*
-
Humans
-
Lapatinib
-
Lymphatic Metastasis
-
Neoplasm Staging
-
Nivolumab
-
Phenylurea Compounds / therapeutic use
-
Prognosis
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
-
Proto-Oncogene Proteins B-raf / genetics*
-
Proto-Oncogene Proteins B-raf / metabolism
-
Pyridines / therapeutic use
-
Pyrrolidines
-
Quinazolines / therapeutic use
-
Randomized Controlled Trials as Topic
-
Survival Analysis
-
Thymine
-
Trastuzumab / therapeutic use
-
Trifluridine / therapeutic use
-
Uracil / analogs & derivatives
-
Uracil / therapeutic use
-
Vascular Endothelial Growth Factor Receptor-1 / antagonists & inhibitors
-
Vascular Endothelial Growth Factor Receptor-1 / genetics*
-
Vascular Endothelial Growth Factor Receptor-1 / metabolism
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Drug Combinations
-
Phenylurea Compounds
-
Pyridines
-
Pyrrolidines
-
Quinazolines
-
trifluridine tipiracil drug combination
-
Lapatinib
-
regorafenib
-
Nivolumab
-
Uracil
-
pembrolizumab
-
Vascular Endothelial Growth Factor Receptor-1
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
Trastuzumab
-
Thymine
-
Trifluridine